Related by context. All words. (Click for frequent words.) 72 ASCO GI 72 Late Breaker 72 Gastrointestinal Cancers Symposium 72 ASCO Annual Meeting 72 CROI 71 ICAAC 71 AACR San Antonio 71 Genitourinary Cancers Symposium 71 ICAAC IDSA 70 AACR NCI EORTC 70 #th Annual Interscience 69 CTRC AACR San Antonio 69 ASCO GU 69 Metastatic Melanoma 69 PROSTVAC TM 68 AASLD Meeting 68 ASH Annual Meeting 68 #th Interscience Conference 68 Poster Discussion 68 AACR #st Annual Meeting 68 Clinical Trial Results 68 Pharmacokinetic 68 Antiviral Activity 68 Hormone Refractory Prostate Cancer 68 NCCTG N# 68 Solid Tumors 68 ASCO abstract 68 AVADO 68 Breast Cancer Symposium 68 Breaking Clinical Trials 67 Randomized Phase 67 viral kinetic 67 ASBMR 67 ORAL Sync 67 AUA Annual Meeting 67 Phase 2b Clinical Trial 67 Platelet Inhibition 67 Clinical Trial Data 67 EORTC 67 #nd EORTC NCI 67 ACR ARHP 67 ECCMID 67 Dose Escalation 67 Phase Ib II 67 Phase Ib study 67 Oral Fingolimod 67 IMPACT DCM 67 HCV SPRINT 67 FOLPI 67 teriflunomide 67 ENDEAVOR IV 67 EORTC NCI AACR 67 Pooled Analysis 66 pertuzumab 66 fosbretabulin 66 CALGB 66 Oral Presentations 66 Preclinical Study 66 AASLD 66 UEGW 66 INCB# [001] 66 BCIRG 66 EASL 66 Selective Cardiac Myosin Activator 66 CAMMS# 66 Transcatheter Cardiovascular Therapeutics TCT 66 Selective Cardiac Myosin 66 NSABP B 66 ADA Scientific Sessions 66 pharmacokinetic PK 66 Aggressive Reduction 66 BRIM3 66 RECORD1 65 Phase III Clinical Trial 65 Brentuximab Vedotin SGN 65 Aflibercept 65 II Clinical Trial 65 EORTC NCI AACR Symposium 65 ECTRIMS 65 Tanespimycin 65 ENDEAVOR III 65 Chicago Multidisciplinary Symposium 65 Placebo Controlled Trial 65 IL# PE#QQR 65 ongoing Phase 1b 65 HCV Protease Inhibitor 65 EuroPCR 65 SUCCEED trial 65 assessing T DM1 65 Phase Ib Clinical Trial 65 oral FTY# 65 subanalysis 65 ECCO ESMO 65 Poster Presentations 65 SPIRIT IV 65 See CLINICAL PHARMACOLOGY 65 preclinical efficacy 65 Prostate AdenoCarcinoma Treatment 65 oral ridaforolimus 65 BRIM2 65 nab paclitaxel 65 EXPAREL ™ 65 Breast Cancer Symposium SABCS 65 Randomized Phase II 65 Digestive Disease Week 65 Stent Thrombosis 65 phase IIIb 65 evaluating mipomersen 65 CRLX# 64 Podium Presentation 64 #rd Annual CTRC 64 Pivotal Phase III 64 Society CTOS 64 CLARITY study 64 crizotinib PF # 64 Pharmacodynamics 64 liposome injection 64 EVEREST II 64 substudy 64 Poster Presentation 64 Pharmacodynamic 64 Digestive Diseases Week 64 Phase IIb Trial 64 Advanced Melanoma 64 recurrent GBM 64 enzastaurin 64 ABCSG 64 Controlled Trial 64 Natalizumab 64 ELACYT 64 AIR2 Trial 64 Combination REOLYSIN R 64 Antitumor activity 64 MERLIN TIMI 64 Phase III ALLEGRO 64 mapatumumab 64 Acute Ischemic Stroke 64 Pivotal Phase 64 Doxil ® 64 pan HDAC inhibitor 64 BARI 2D 64 sipuleucel T 64 HuMax EGFr 64 Study Evaluating 64 Hsp# Inhibitor 64 Tumor Response 64 Long Term Efficacy 64 Sipuleucel T 64 Antitumor Activity 64 AACR #nd Annual Meeting 64 PERSEUS 64 HER2 positive metastatic breast 64 Preclinical Data 64 Pivotal Clinical Trial 64 Immunogenicity 64 Randomized Double blind 64 alpha 2a 64 standard chemotherapy regimen 64 ExTRACT TIMI 64 EOquin TM 64 elotuzumab 64 Castration Resistant Prostate Cancer 64 ATACAND 64 neratinib 64 Prospective Multicenter 64 BIOCOM Investor Conference 64 Hemodialysis Patients 64 Connective Tissue Oncology 64 ASGT 64 Neoadjuvant 64 STRIDE PD 64 HDAC Inhibitor 64 Phase Ib clinical 64 pharmacokinetic PK study 64 entitled Synergistic 63 RE LY ® 63 Pemetrexed 63 Endocrine Society Annual Meeting 63 Abstract Number 63 Anti Tumor Activity 63 viral kinetics 63 HCV RESPOND 2 63 Phase IIB 63 Phase 1b trial 63 CARE HF 63 RE LY trial 63 Prospective Randomized 63 Carfilzomib 63 Initiated Phase 63 GAMMAGARD 63 MEND CABG 63 multicenter Phase 63 axitinib 63 SPIRIT FIRST 63 Digestive Disease Week DDW 63 TG MV 63 ASCO Breast Cancer 63 subgroup analyzes 63 Clinical Oncology Annual Meeting 63 Advanced Solid Tumors 63 metastatic castration resistant 63 Adjuvant Chemotherapy 63 Antiviral Therapy 63 pomalidomide 63 Adjuvant Therapy 63 Xelox 63 Relapsing Multiple Sclerosis 63 Cardiotoxicity 63 Traficet EN 63 CTAP# Capsules 63 Newly Diagnosed Multiple Myeloma 63 PRECiSE 63 BOLDER II 63 Phase 2b Study 63 HORIZONS AMI 63 Peginterferon 63 YONDELIS 63 Tezampanel 63 nonclinical studies 63 sorafenib Nexavar 63 JAK Inhibitor 63 Phase IIb Clinical Trial 63 oral Xeloda 63 Clinical Outcome 63 Randomized Double Blind Placebo 63 Oral Presentation 63 Glufosfamide 63 GOUT 63 Randomized Clinical Trial 63 Bortezomib 63 Survival Benefit 63 evaluating tivozanib 63 TAXUS ATLAS 63 Patients Treated With 63 Parathyroid Hormone 63 nd Annual Meeting 63 neoadjuvant treatment 63 Zenvia Phase III 63 Autologous Stem Cell Transplantation 63 KRN# 63 randomized discontinuation trial 63 sorafenib tablets 63 Advanced Neuroendocrine Tumors 63 FASLODEX 63 LUX Lung 63 ISPOR 63 Bezielle 63 TLK# 63 Tolerability 63 Chronic Hepatitis C 63 FOLOTYN ® 63 PROSTASCINT R 63 PSN# [002] 63 Ozarelix 63 ENESTnd 63 GRAVITAS trial 63 Molecular Targets 63 ORENCIA ® 63 Patient Outcomes 63 cediranib 63 Symposium SABCS 63 Patients Receiving 63 AZILECT R 63 tipranavir 63 ASCO Genitourinary Cancers Symposium 63 Clinical Efficacy 63 Safinamide 63 SA FC# 62 Ranolazine 62 Azedra 62 TASKi2 62 trastuzumab Herceptin R 62 vitro cytotoxicity 62 Renal Cell Carcinoma 62 USpella 62 PEG SN# 62 Pharmacokinetics PK 62 Hedgehog Pathway Inhibitor 62 San Antonio Breast Cancer 62 HCV Genotype 62 Phase #/#a trial 62 phase IIb clinical 62 Double Blind Placebo 62 F FDG PET 62 ESMO 62 placebo controlled clinical 62 galiximab 62 ritonavir boosted 62 PreCISe 62 Prostate Cancer Symposium 62 Improved Survival 62 preclinical pharmacokinetic 62 RE LY 62 INC# 62 phase IIb study 62 AHA Scientific Sessions 62 clevidipine 62 Dose Ranging Study 62 Phase III Clinical Trials 62 Pharmacokinetic Study 62 alvespimycin 62 Advanced Renal Cell 62 Telbivudine 62 Activator CK # 62 Aromatase Inhibitors 62 ibandronate 62 ONTARGET 62 Tesetaxel 62 Recurrent Chest Wall 62 AACR IASLC Joint 62 Phase IIIb clinical 62 RECIST Response Evaluation Criteria 62 Metastatic Prostate Cancer 62 Urocortin 2 62 Venous Thromboembolism 62 Pivotal Study 62 TRANSFORMS 62 Hematological Malignancies 62 radezolid 62 PEG IFN 62 PROactive Study 62 relapsed MM 62 CALGB # [002] 62 Intervention Effectiveness 62 iPrEx 62 Hematology ASH Annual Meeting 62 Ocrelizumab 62 Liver Metastases 62 FOLFOX6 chemotherapy regimen 62 Surgical Treatment 62 Relapsed Multiple Myeloma 62 Placebo Controlled Study 62 Therapeutics TCT scientific 62 cetuximab Erbitux R 62 Fulvestrant 62 Aggressive Drug Evaluation 62 CIMZIA TM certolizumab pegol 62 Aliskiren 62 PCI ExTRACT TIMI 62 Trodusquemine MSI 62 FOLFIRI 62 Annual Scientific Sessions 62 multicenter trials 62 Monotherapy 62 Randomized Double Blind 62 ZOLINZA 62 Phase 2b Trial 62 RTOG 62 Meets Primary Endpoint 62 European CanCer Organisation ECCO 62 HORIZONS AMI trial 62 Protease Inhibitors 62 AVOREN 62 recurrent glioblastoma multiforme 62 gefitinib Iressa 62 ganetespib 62 alfa 2a 62 Randomized Study 62 Endocrine Society #st 62 Well Tolerated 62 candesartan cilexetil 62 CIMZIA ™ 62 Demonstrates Efficacy 62 Phase III Trial 62 Hepatocellular Carcinoma 62 5 Fluorouracil 62 Elagolix 62 Presents Preclinical Data 62 Adjuvant Treatment 62 Glucosamine Chondroitin Arthritis 62 prucalopride 62 Double Blind Randomized 62 Chemophase 62 Hematology Annual Meeting 62 TRO# 62 DASISION 62 Quinamed 62 Capecitabine 62 BARACLUDE ® 62 ACCOMPLISH 62 novel VDA molecule 62 IRX 2 62 APPRAISE 62 ACUITY trial 62 Pharmacokinetic PK 62 SYNTAX trial 62 mg administered orally 62 ENDEAVOR II 62 ARVO 61 multicenter phase 61 solithromycin 61 PEGylated interferon beta 1a 61 immunomodulatory agents 61 PXD# 61 ACRIN 61 Cloretazine ® 61 telaprevir dosing 61 FOLFOX6 61 AACR symposium 61 randomized multicenter Phase III 61 Zoledronic Acid 61 IMPACT IMmunotherapy 61 Phase 2a Clinical Trial 61 ADAGIO study 61 Systemic Sclerosis 61 relapsed MCL 61 ASSERT trial 61 Phase 2a Trial 61 Prolongs Survival 61 trastuzumab DM1 T DM1 61 multicenter Phase II 61 Sandostatin R 61 BiTE antibody MT# 61 Neoadjuvant Chemotherapy 61 Antigen Specific 61 colesevelam HCl 61 LUMINATE 61 CUSTOM III 61 Folfox 61 NO# [002] 61 randomized controlled Phase 61 DCE MRI 61 PROVENGE sipuleucel T 61 CHARM Added 61 Dual Antiplatelet Therapy 61 dose escalation trial 61 PROSTVAC ® 61 CR# vcMMAE 61 Ambrisentan 61 pegylated liposomal doxorubicin 61 R roscovitine 61 R rosiglitazone maleate 61 Dose Response 61 Betaferon ® 61 APTIVUS 61 REYATAZ R 61 SVR# 61 Poster Session 61 phase IIb trial 61 EASD 61 dosing cohort 61 PDX pralatrexate 61 pharmacodynamic effects 61 Refractory Angina 61 EORTC NCI 61 MEK Inhibitor 61 ZYBRESTAT TM 61 Previously Treated 61 Postmenopausal Women 61 Targretin 61 Carotid Revascularization Endarterectomy vs. 61 Tyrosine Kinase Inhibitor 61 TMC# [002] 61 thalidomide Thalomid 61 postmenopausal osteoporotic women 61 brivaracetam 61 PSMA ADC 61 XL# SAR# 61 angiographic outcomes 61 ASCO 61 Taxotere ® 61 Rheumatology ACR Annual 61 ixabepilone 61 Androxal TM 61 CLL8 61 Bazedoxifene 61 Pivotal Trial 61 DDP# 61 Investigational Compound 61 Lung Cancer Trial 61 interferon gamma 1b 61 RhuDex TM 61 Pediatric Academic Societies PAS 61 IFN α 61 Immunotherapeutic 61 phase IIb 61 NEUVENGE 61 Phase 1b 61 Triapine R 61 virus HCV protease inhibitor 61 Randomized Controlled 61 LibiGel ® 61 Shows Efficacy 61 BR.# 61 evaluating carfilzomib 61 ZD# [001] 61 Valopicitabine 61 Cell Lymphoma 61 PROactive study 61 CIMZIA TM 61 Vitaxin 61 Patient Enrollment 61 Anticancer Drugs 61 Heart Failure Patients 61 prospective multicenter study 61 Prognostic Significance 61 Pharmacokinetics 61 Epoetin Alfa 61 Stent Restenosis 61 Dacogen injection 61 Pegylated Interferon 61 BENICAR HCT 61 oral rivaroxaban 61 Valopicitabine NM# 61 Phase IIIb 61 PRECISE 61 Colorectal Cancer Patients 61 Inflammatory Arthritis 61 Alocrest 61 Inhalation Solution 61 Virulizin ® 61 Myelodysplastic Syndromes 61 forodesine 61 R lenalidomide 61 oral prodrug 61 League Against Rheumatism 61 dose escalation clinical 61 Bosentan 61 Targeted Therapies 61 TMC# C# 61 varespladib 61 Abstract # 61 delafloxacin 61 Vicriviroc 61 randomized Phase III 61 annual Transcatheter Cardiovascular 61 Mycophenolate Mofetil 61 Annual Interscience Conference 61 International Myeloma Workshop 61 farletuzumab 61 Meta Analysis 61 EURIDIS 61 treatment naive genotype 61 MYCAMINE 61 INCB# [003] 61 NATRECOR ® 61 decitabine 61 ThermoDox R 61 PROTECT AF 61 Dapagliflozin 61 dual endothelin receptor antagonist 61 chemoradiation therapy 61 lexidronam injection 61 Investigational Drug 61 ROCKET AF 61 DOXIL 61 Percutaneous Tibial Nerve Stimulation 61 Cachexia 61 Uterine Fibroid Embolization 61 SCCHN 61 verteporfin 61 PANVAC VF 61 metastatic hormone refractory 61 ON #.Na 61 Dr. Pingpank 60 Tipranavir 60 Acute Coronary Syndromes 60 Treatment Naive Patients 60 Dendritic Cells 60 Anti Tumor 60 PegIFN RBV 60 Sangamo BioSciences Announces 60 Nymox NX 60 PROLARIS 60 Amrubicin 60 longitudinal observational study 60 Safety Tolerability 60 rALLy trial 60 Naive Patients 60 AA Amyloidosis 60 NCIC CTG 60 Valsartan 60 clinical pharmacology studies 60 CoFactor 60 Tiotropium 60 catheter occlusion 60 Fondaparinux 60 cetuximab Erbitux 60 RAPAFLO R 60 huN# DM1 60 epoetin alpha 60 PIX# [002] 60 Biological Therapy 60 Xeloda ® 60 Chronic Myeloid Leukemia 60 MEND CABG II 60 Sapacitabine 60 lintuzumab 60 Solorel TM 60 multicenter placebo controlled 60 Treated Patients 60 Randomized trials 60 glatiramer acetate 60 EFNS 60 Muraglitazar 60 Phase 2a Study 60 Neulasta ® 60 ID NCT# 60 Aortic Stenosis 60 CYT# potent vascular disrupting 60 J Clin Oncol 60 Deforolimus 60 secondary efficacy endpoints 60 SPIRIT III 60 Phase 2b study 60 NSABP 60 Glatiramer Acetate 60 mycophenolate mofetil 60 riociguat 60 Transcatheter Cardiovascular Therapeutics 60 DAPT 60 Femara letrozole 60 inhibitor RG# 60 Topline Results 60 First Patient Enrolled 60 Randomized Comparison 60 Squalamine 60 Acute Heart Failure 60 GSK# [001] 60 Myelodysplastic Syndrome MDS 60 AEGR 60 Prospective Randomized Trial 60 Panzem R NCD 60 Stereotactic Body Radiation Therapy 60 Controlled Study 60 Kinase Inhibitor 60 PRECISE trial 60 Diabetic Macular Edema DME 60 LymphoStat B 60 transthyretin TTR mediated amyloidosis 60 Metastatic Renal Cell Carcinoma 60 Calcium Acetate 60 Phase 1a clinical 60 Genasense ® oblimersen 60 MADIT CRT trial 60 #F FDG PET 60 fluvastatin 60 Sorafenib HCC Assessment 60 Clinical Antipsychotic Trials 60 Romidepsin 60 neoadjuvant 60 phase 2a 60 florbetaben 60 nonrandomized 60 Novel Small Molecule 60 placebo controlled Phase III 60 eprotirome 60 bazedoxifene conjugated estrogens 60 Interferon Gamma 60 histone deacetylase HDAC inhibitor 60 Breaking Clinical Trial 60 GW# [003] 60 CTRC AACR 60 davunetide intranasal AL 60 elagolix 60 Multiple Myeloma MM 60 Phase 2b 60 Plus Ribavirin 60 Polymerase Inhibitor 60 ISTODAX ® 60 Phase #b/#a clinical 60 phase Ib 60 Therapeutics TCT 60 Pharmacokinetic parameters 60 PRESEPT 60 Hepatotoxicity 60 Acute Myocardial Infarction 60 Therapeutic Approaches 60 Kahalalide F 60 Adjunctive Therapy 60 demonstrated antitumor activity 60 vidofludimus 60 dose cohort 60 Outpatient Setting 60 Initiate Clinical Trial 60 targeting CD# 60 Randomized Controlled Trials 60 registrational Phase 60 Gemcitabine 60 Metastatic Colorectal Cancer 60 HDL Selective Delipidation 60 Microplasmin 60 budesonide foam 60 Catheter Ablation 60 RCW breast cancer 60 pegylated interferon alfa 2b 60 Romiplostim 60 NMIBC 60 satraplatin Phase 60 sNDA submission 60 ACCLAIM 60 MAGE A3 ASCI 60 pharmacodynamic parameters 60 TACI Ig 60 HGS ETR2 60 randomized Phase IIb 60 Interferon Beta 60 q#h 60 Interferon beta 1a 60 CCX# 60 phase IIa clinical 60 Phase 1b clinical trials 60 CYPHER ® Sirolimus eluting 60 Diabetic Macular Edema 60 VEITHsymposium 60 QLT# 60 cannabinor 60 Completes Patient Enrollment 60 Taxotere R 60 Phase III randomized controlled 60 Truvada tablets 60 Tesmilifene 60 plus prednisone 60 atazanavir sulfate 60 aflibercept 60 HIF PHI 60 Pemphigus Vulgaris 60 peg interferon 60 Golimumab 60 Neuroprotective Effects 60 tanespimycin 60 EGS# 60 CombAT 60 OPT CHF 60 aclidinium 60 NEO3 60 Phase III Trials 60 Gastrointestinal Cancer 60 ZACTIMA 60 Treatment Naïve 60 gemcitabine carboplatin 60 Anticancer Activity 60 AZILECT ® 60 Bladder Cancer 60 Phase III psoriasis 60 phase IIa 60 Degarelix 60 Complete Remission 60 Patients Treated 60 Drug Eluting 60 Emerging Therapies 60 Guanilib 60 SWOG 60 Decitabine 60 Gastric Cancer 60 MERIT ES 60 ADVANCE PD 60 Virologic 60 acute PAO 60 Carotid Stenting 60 Edge STudy 60 Myocardial Infarction Study 60 docetaxel Taxotere ® 60 Pegylated Liposomal Doxorubicin 60 ularitide 60 Ophena TM 60 CHAMPION PLATFORM 59 PRTX 59 Elocalcitol 59 Carotid Endarterectomy 59 Aplidin R 59 posaconazole 59 MGd 59 Randomized Phase III 59 Irinotecan 59 SYMMETRY trial 59 Hematology Meeting 59 Pivotal Trials 59 non nucleoside inhibitor 59 Enzastaurin 59 Arteriosclerosis Thrombosis 59 Pertuzumab 59 Efficacy Results 59 Cutaneous T 59 chemotherapy gemcitabine 59 CALERIE 59 favorable pharmacokinetic profile 59 TDF FTC 59 EDEMA3 trial 59 Cardiostim 59 Temsirolimus 59 ® pioglitazone HCl 59 AACR Meeting 59 FOLFOX4 59 Renal Function 59 Blinatumomab 59 NASDAQ CYTK announced 59 mg/m2 dose 59 AIR CF1 59 ACAPODENE 59 ILLUMINATE 59 Kidney Transplant Patients 59 INFERGEN 59 Subgroup analysis 59 Clostridium difficile Infection 59 2 methoxyestradiol 59 Drug Candidate 59 Orally Active 59 neurologic progression 59 ASCO Gastrointestinal Cancers Symposium 59 Product Monograph 59 Phase 2a clinical 59 Phase IIIb study 59 controlled multicenter Phase 59 TO AVOID PREGNANCY WHILE 59 trastuzumab emtansine T DM1 59 Opportunistic Infections CROI 59 velafermin 59 Phase III ADT 59 depsipeptide 59 Targeted Therapy 59 PARTNER Trial 59 metastatic renal cell carcinoma 59 ASTRO Annual Meeting 59 Pulmonary Arterial Hypertension 59 Hormone Receptor Positive 59 multicentre randomized 59 Trastuzumab 59 sunitinib Sutent 59 Pafuramidine 59 st Annual Meeting 59 VADT 59 Demonstrates Sustained 59 XELOX 59 Pirfenidone 59 ARBITER 6 59 Betaferon R 59 Annual ICAAC 59 Novel Inhibitor 59 trastuzumab DM1 59 LCP Tacro ™ 59 plasma pharmacokinetics 59 Overactive Bladder 59 ezetimibe simvastatin 59 prospective multicenter 59 Fluorouracil 59 randomized multicenter trial 59 RADIANT 59 Antithrombotic 59 zotarolimus eluting stent 59 CHAMPION PCI 59 Secondary efficacy endpoints 59 NEVO RES 59 Kamada AAT 59 prospective multicentre 59 Trofex 59 chemoradiotherapy 59 Breast Density 59 hormone refractory metastatic prostate 59 Antiangiogenic 59 Bivalirudin 59 NDA Submission 59 Patient Recruitment 59 Velcade bortezomib 59 Cancer Vaccines 59 Vascular Annual Meeting 59 Improves Survival 59 Clinical Oncology ASCO Annual 59 trials RCTs 59 Capsule Endoscopy 59 Chronic Lymphocytic Leukemia CLL 59 evaluating Vectibix 59 ASCRS 59 Peginterferon Alfa 2a 59 Inflammatory Bowel Diseases 59 LENALIDOMIDE 59 Fecal Incontinence 59 pharmacokinetic pharmacodynamic 59 pharmacodynamic 59 APOPTONE 59 mRCC 59 BAL# [002] 59 CANCIDAS 59 KRAS status 59 Angiographic 59 Randomized Clinical Trials 59 Hycamtin ® 59 placebo controlled Phase 59 SPRYCEL ® 59 RGB # 59 ToGA 59 unfractionated heparin UFH 59 huC# DM4 59 genitourinary cancers 59 EDEMA3 59 IIa trial 59 Blind Placebo Controlled Trial 59 Recurrent Breast Cancer 59 DermaVir Patch 59 p# biomarker 59 plus Copegus R 59 Investigational Agent 59 AVERROES 59 prospective observational 59 Phase III AFFIRM 59 recurrent glioma 59 HuMax CD4 59 Chronic Lymphocytic Leukemia 59 number NCT# ClinicalTrials.gov 59 VIVUS Qnexa 59 trastuzumab Herceptin 59 Bevacizumab 59 PRE SURGE 59 fallopian tube cancers 59 Renal Cell Carcinoma RCC 59 AACR Frontiers 59 INSPIRE Trial Phase III 59 FDA Approvable Letter 59 mGluR5 negative 59 cinacalcet 59 antitumour activity 59 PEGINTRON TM 59 abacavir lamivudine 59 Lenocta 59 Androgen Receptor 59 ORMD 59 Severe Sepsis 59 iSBTc 59 Therapeutic Advances 59 sunitinib malate 59 Omacetaxine 59 desvenlafaxine succinate 59 pharmacokinetics PK 59 tolvaptan 59 Exemestane 59 Anticancer Drug 59 dosing cohorts 59 refractory chronic lymphocytic 59 BIBW 59 rNAPc2 59 CLL SLL 59 prostate cancer mCRPC 59 oral deforolimus 59 Valortim R 59 Clolar ® 59 ponatinib 59 ALGRX 59 fidaxomicin Phase 3 59 Cloretazine R VNP#M 59 Benign Prostatic Hyperplasia 59 Liposomal 59 Celecoxib APC trial 59 Cancer Immunotherapy 59 Demonstrates Significant 59 Percutaneous Coronary Intervention 59 Archexin 59 PFO migraine 59 ENMD # 59 RNAi Therapeutic 59 Thiovir 59 UPLYSO 59 recurrent malignant glioma 59 Novel Oral 59 FDG PET imaging 59 phase IIb III 59 ACTEMRA TM 59 Relapsed Refractory Multiple Myeloma 59 Phase III VISTA 59 adecatumumab 59 Anthracycline 59 EULAR 59 multicenter prospective 59 HoFH 59 Cethromycin 59 HGS ETR1 59 efficacy endpoint 59 paclitaxel Taxol R 59 Proxinium TM 59 Clinical Trial Evaluating 59 Eluting Stent 59 DDW 59 mertansine 59 Teriflunomide 59 Vandetanib 59 pioglitazone HCl 59 Seliciclib 59 BCX# 59 GFT# 59 erlotinib Tarceva ® 59 papillary renal cell carcinoma 59 ST Segment Elevation 59 Demonstrates Potent 59 Subgroup Analysis 59 APTIVUS R 59 vismodegib 59 TYKERB 59 Clinical Outcomes Utilizing Revascularization 59 motesanib diphosphate 59 Genitourinary Cancer 59 Arch Neurol 59 DNA methylation markers 59 Neoplasia 59 colorectal liver metastases 59 FDG PET 59 orally administered inhibitor 59 refractory multiple myeloma 59 Unfractionated Heparin 59 Intravitreal 59 REVLIMID R